30 closest matches · ranked by relevance
Lambert Eaton Myasthenic Syndrome
Primary: Change From Baseline Quantitative Myasthenia Gravis (QMG) at 14 Days — 5.6; 6.4; 7.9; 6.7 QMG Score — p=0.0452
Lambert-Eaton Myasthenic Syndrome · Eaton-Lambert Myasthenic Syndrome
Primary: Number of Participants With 30% or More Deterioration in Triple Timed Up & Go (3TUG) Test, Compared to Time-matched Baseline — 0; 13 Participants — p=<0.0001
Lambert-Eaton Myasthenic Syndrome
Primary: Quantitative Myasthenia Gravis (QMG) Score — 7.8; 8.5; 7.9; 15.0 scores on a scale — p=0.0004
Lymphangioleiomyomatosis · Lymphangiomyomas · Pleural Effusions
Primary: Number of Participants With a Reduction in Total Tumor Volume of at Least 20%. — 0 Participants
Lymphangioleiomyomatosis
Primary: Rate of Change in Forced Expiratory Volume in 1 Second in ml/Month — 1.04; 1.66 milliliters per month — p=0.4
Myasthenic Syndromes, Congenital
Primary: Subject Global Impression (SGI) Score Summary: Mann-Whitney Main Effects Test Results; SGI Score Mixed Model Analysis — -0.13; -1.75; -0.75; -1.14 Scores on a scale…
Lymphangioleiomyomatosis
Primary: Changes in Forced Expiratory Volume in One-second (FEV1) Slope in Milliliters Per Month — 1; -12 milliliters per month — p=<0.001
Paraneoplastic Syndromes
Primary: Survival of Patients With Paraneoplastic Disease Who Are Treated With Tacrolimus — 48 months
Lymphangioleiomyomatosis
Primary: Serum VEGF-D — 0.05; 0.07 Log transformed VEGF-D change pg/dL
Myasthenia Gravis, Generalized
Primary: Myasthenia Gravis-Activities of Daily Living (MG-ADL) Summary by Time Point and Myasthenia Gravis Type: Wilcoxon-Mann-Whitney Rank Sum Test Results — 4.96; 3.86; 6.14…
Myasthaenia Gravis
Primary: Mean Change From Baseline for Quantitative Myasthenia Gravis (QMG) Score at Week 24 — -2.37; -4.21 Units on a scale — p=0.256
Neoplasms
Primary: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment — 20; 40 Percentage of participants
Muscle Weakness
Primary: Percent Change in the Amplitude of Evoked Compound Muscle Action Potential by Electromyography Between the First to Fifth Response — 0 percent change
Neuroendocrine Tumors
Primary: Tumor Response Rate Measured by the Response Evaluation Criteria in Solid Tumors (RECIST) — 0; 0; 0; 8 participants
Lymphangioleiomyomatosis
Primary: Serum Vascular Endothelial Growth Factor-D (VEGF-D) Levels After Treatment With a Combination of Resveratrol and Sirolimus as Compared to Baseline Serum VEGF-D Levels on…
Gastrointestinal Motility Disorder · Intestinal Disease
Primary: Effect of Lanreotide on Gastrointestinal Motility as Measured by Smart Pill — 371.52; 392; 4767; 5159 minutes — p=0.07
Myasthenia Gravis
Primary: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Grade 3 or Higher TEAEs, and Adverse Event (AE) Leading to…
Sporadic Amyotrophic Lateral Sclerosis
Primary: Percentage of Participants That Discontinued Study Drug — 5; 32; 5 percentage of participants
Lymphangioleiomyomatosis
Primary: Change From Baseline in Vascular Endothelial Growth Factor-D (VEGF-D) Concentrations — -464.3; -1113.2; -1771.7 pg/mL
Primary Inoperable Thymoma · Local Recurrent Thymoma
Primary: Percent Change in Tumor Volume From Baseline to EOS — -37.38 percentage of tumor volume
Sporadic Amyotrophic Lateral Sclerosis
Primary: Change in Resting Motor Threshold — -2.430; 0.805; 4.746; 1.465 percentage of maximum stimulus output — p=0.039
Neuroendocrine Tumours
Primary: Disease Control Rate (DCR) Assessed Locally at Month 9 — 35.0; 45.2; 45.0 percentage of participants — p=0.2968
Amyotrophic Lateral Sclerosis
Primary: Change in Muscle Strength From Baseline — 74.7; 74.7; 76.4; 74.5 units on a scale — p==0.001
Limited Stage Small Cell Lung Cancer · Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 14.5; 10.7 months
Lymphangioleiomyomatosis
Primary: Number of Sirolimus-Sensitive Plasma Protein Biomarkers in Lymphangioleiomyomatosis (LAM) Participants — 662 plasma proteins
Amyotrophic Lateral Sclerosis
Primary: Safety of Intramuscular Injections of Engensis in Participants With Amyotrophic Lateral Sclerosis Compared to Placebo — 4; 3; 3; 1 Participants
ALS (Amyotrophic Lateral Sclerosis)
Primary: Change in Revised ALS Functional Rating Scale (ALSFRS-R) — 0.44 points per month — p=0.99
Neuroendocrine Carcinoma of the Lung and Thymus
Primary: Percentage of Participants Progression-free at 9 Months Based on Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1) — 0; 0; 0; 2.4 percentage of participants
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…